🔎 Trials Near Me

Home › Chronic Kidney Disease › NCT02411773

Sympatholysis in Chronic Kidney Disease

RecruitingPhase 1Healthy volunteers welcome

Functional Sympatholysis and Exercise Intolerance in Chronic Kidney Disease

Who can join

Ages 18 to 75 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* Veterans with Stages III and IV Chronic Kidney Disease (CKD)
* Kidney transplant recipients with varying degrees of kidney function
* Veterans 18-75 years old, without kidney disease, as study controls
* Exercise less than 20 minutes twice per week
* Willing and able to cooperate with the protocol

Exclusion Criteria:

* Severe CKD (estimated glomerular filtration rate (eGFR) \< 15 cc/minute)
* Metabolic alkalosis (serum bicarbonate \> 28 meq/L)
* Ongoing drug or alcohol abuse
* Diabetic neuropathy
* Any serious systemic disease that might influence survival
* Severe anemia with hemoglobin (Hbg) level \< 10 g/dL
* Clinical evidence of congestive heart failure or ejection fraction below 35%
* Symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history
* Treatment with central alpha agonists (clonidine)
* Uncontrolled hypertension with blood pressure (BP) greater than 170/100 mmHg
* Low blood pressure with BP less than 100/50 mmHg
* Pregnancy or plans to become pregnant
* Current treatment with monoamine oxidase inhibitors (MAOIs)
* Inability to exercise on a stationary bicycle

About the study

The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate).

What is being tested

Sponsor: Emory University · Participants: 110 · Started: Jun 11, 2015

Contact the study team

Official record on ClinicalTrials.gov — NCT02411773

Locations in the U.S.

GeorgiaAtlanta VA Medical Center, Decatur

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.